文献速递儿科与产科急症重症综合管理与镇静镇痛

高剂量促红细胞生成素与缺血缺氧性脑病新生儿循环生物标志物及神经发育结局的关联:HEAL随机临床试验的二次分析

Association of High-Dose Erythropoietin With Circulating Biomarkers and Neurodevelopmental Outcomes Among Neonates With Hypoxic Ischemic Encephalopathy: A Secondary Analysis of the HEAL Randomized Clinical Trial.
PubMed 文献 · JAMA Netw Open · 2023-07-03
一句话结论HEAL试验二次分析显示,高剂量促红细胞生成素未降低HIE新生儿神经炎症或脑损伤生物标志物,循环生物标志物仅轻度改善2年死亡或神经发育损害预测(AUC 0.73升至0.79)。

本研究为HEAL随机临床试验的预计划二次分析,纳入美国17个学术中心23个新生儿重症监护病房的500例胎龄≥36周的中度或重度缺血缺氧性脑病(HIE)新生儿,干预为促红细胞生成素1000 U/kg/剂,于第1、2、3、4、7天给药。在180例完成生物标志物分析的婴儿中,促红细胞生成素组第2天和第4天促红细胞生成素浓度较基线升高,但未改变其他生物标志物浓度(如第4天IL-6组间差值-1.3 pg/mL,95%CI -4.8至2.0 pg/mL)。校正多重比较后,6种血浆生物标志物(基线C5a、IL-6、神经元特异性烯醇化酶;第4天IL-8、tau、泛素羧基末端水解酶L1)较单纯临床数据显著改善2年死亡或神经发育损害的估计,但改善幅度有限,AUC从0.73(95%CI 0.70-0.75)升至0.79(95%CI 0.77-0.81;P=0.01),对应正确分类风险提高16%(95%CI 5%-44%)。结论认为促红细胞生成素未降低HIE婴儿神经炎症或脑损伤生物标志物,循环生物标志物仅轻度改善2年结局估计。

要点

  • 在180例HEAL试验婴儿中,促红细胞生成素1000 U/kg/剂于第1、2、3、4、7天给药,未改变其他生物标志物浓度(第4天IL-6组间差值-1.3 pg/mL,95%CI -4.8至2.0 pg/mL)。
  • 6种血浆生物标志物(基线C5a、IL-6、神经元特异性烯醇化酶;第4天IL-8、tau、泛素羧基末端水解酶L1)较临床数据改善2年死亡或NDI预测,AUC从0.73(95%CI 0.70-0.75)升至0.79(95%CI 0.77-0.81;P=0.01)。
  • 生物标志物 panel 使2年死亡或NDI风险正确分类提高16%(95%CI 5%-44%)。
  • 促红细胞生成素组第2天和第4天促红细胞生成素浓度较基线升高。
  • 促红细胞生成素未降低HIE婴儿神经炎症或脑损伤生物标志物。

适用人群与场景

  • 胎龄≥36周、中度或重度HIE新生儿,来自美国17个学术中心23个新生儿重症监护病房,2017年1月25日至2019年10月9日招募,随访至2022年10月。
  • 生物标志物分析纳入180例有基线(第0/1天)、第2天和第4天血浆样本且死亡或完成2年Bayley婴幼儿发育量表III评估的婴儿。

处置流程与药物剂量

  • 促红细胞生成素1000 U/kg/剂,于第1、2、3、4、7天给药(途径原文未写明)。

研究设计与关键结果

  • 研究类型:HEAL随机临床试验的预计划二次分析,纳入500例胎龄≥36周的中度或重度HIE新生儿,干预为促红细胞生成素1000 U/kg/剂于第1、2、3、4、7天给药(n=500),对照为安慰剂(原文未明确描述对照),主要终点为2年死亡或神经发育损害。
  • 生物标志物亚组180例,平均(SD)胎龄39.1(1.5)周,83例(46%)为女性。
  • 促红细胞生成素组第2天和第4天促红细胞生成素浓度较基线升高。
  • 促红细胞生成素未改变其他生物标志物浓度:第4天IL-6组间差值-1.3 pg/mL(95%CI -4.8至2.0 pg/mL)。
  • 校正多重比较后,6种血浆生物标志物(基线C5a、IL-6、神经元特异性烯醇化酶;第4天IL-8、tau、泛素羧基末端水解酶L1)较单纯临床数据显著改善2年死亡或NDI估计,AUC从0.73(95%CI 0.70-0.75)升至0.79(95%CI 0.77-0.81;P=0.01),正确分类提高16%(95%CI 5%-44%)。

证据类型、等级与局限

  • 证据类型:随机对照试验的预计划二次分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,促红细胞生成素治疗未降低HIE婴儿神经炎症或脑损伤生物标志物,循环生物标志物仅轻度改善2年结局估计。

指南或共识出处

  • JAMA Network Open发表;试验注册号ClinicalTrials.gov NCT02811263。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: The ability to predict neurodevelopmental impairment (NDI) for infants diagnosed with hypoxic ischemic encephalopathy (HIE) is important for parental guidance and clinical treatment as well as for stratification of patients for future neurotherapeutic studies.

OBJECTIVES: To examine the effect of erythropoietin on plasma inflammatory mediators in infants with moderate or severe HIE and to develop a panel of circulating biomarkers that improves the projection of 2-year NDI over and above the clinical data available at the time of birth.

DESIGN, SETTING, AND PARTICIPANTS: This study is a preplanned secondary analysis of prospectively collected data from infants enrolled in the High-Dose Erythropoietin for Asphyxia and Encephalopathy (HEAL) Trial, which tested the efficacy of erythropoietin as an adjunctive neuroprotective therapy to therapeutic hypothermia. The study was conducted at 17 academic sites comprising 23 neonatal intensive care units in the United States between January 25, 2017, and October 9, 2019, with follow-up through October 2022. Overall, 500 infants born at 36 weeks' gestation or later with moderate or severe HIE were included.

INTERVENTION: Erythropoietin treatment 1000 U/kg/dose on days 1, 2, 3, 4 and 7.

MAIN OUTCOMES AND MEASURES: Plasma erythropoietin was measured in 444 infants (89%) within 24 hours after birth. A subset of 180 infants who had plasma samples available at baseline (day 0/1), day 2, and day 4 after birth and either died or had 2-year Bayley Scales of Infant Development III assessments completed were included in the biomarker analysis.

RESULTS: The 180 infants included in this substudy had a mean (SD) gestational age of 39.1 (1.5) weeks, and 83 (46%) were female. Infants who received erythropoietin had increased concentrations of erythropoietin at day 2 and day 4 compared with baseline. Erythropoietin treatment did not alter concentrations of other measured biomarkers (eg, difference in interleukin [IL] 6 between groups on day 4: -1.3 pg/mL; 95% CI, -4.8 to 2.0 pg/mL). After adjusting for multiple comparisons, we identified 6 plasma biomarkers (C5a, interleukin [IL] 6, and neuron-specific enolase at baseline; IL-8, tau, and ubiquitin carboxy-terminal hydrolase-L1 at day 4) that significantly improved estimations of death or NDI at 2 years compared with clinical data alone. However, the improvement was only modest, increasing the AUC from 0.73 (95% CI, 0.70-0.75) to 0.79 (95% CI, 0.77-0.81; P = .01), corresponding to a 16% (95% CI, 5%-44%) increase in correct classification of participant risk of death or NDI at 2 years.

CONCLUSIONS AND RELEVANCE: In this study, erythropoietin treatment did not reduce biomarkers of neuroinflammation or brain injury in infants with HIE. Circulating biomarkers modestly improved estimation of 2-year outcomes.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02811263.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Juul SE, Voldal E, Comstock BA, et al. Association of High-Dose Erythropoietin With Circulating Biomarkers and Neurodevelopmental Outcomes Among Neonates With Hypoxic Ischemic Encephalopathy: A Secondary Analysis of the HEAL Randomized Clinical Trial. JAMA Netw Open. 2023. PMID: 37418263. doi:10.1001/jamanetworkopen.2023.22131

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。